Based on the fact that stevioside, a glycoside obtained from Stevia rebaudiana Bert has the chief characteristic of regulating hyperglycemic episodes. The present nutraceutical research describes an innovation that stevia product containing jelly based formulations have not yet designed as hypoglycemic aids for over-the-counter (OTC) prospective. The main objectives of this study involved the development of edible jelly formulations containing stevioside which will impart glucose lowering as well as artificial sweetening characteristics, just like edible jelly brand products such as Juzt Jelly®, Jelly Belly®, Boleto®, Jolly Candy®, FrutBite® in India. Therefore, the diabetic patients will get a better hypoglycemic control, non-calorific product, will also enjoy the sweetness, patient-friendly, convenient, without specific dose and frequency and will be much cheaper than existing market products. The formulation was prepared by the heating method which comprises of stevioside, HPMC K100, HPMC K15, sodium metabisulphite, ascorbic acid, glycerine, propylene glycol, triethanolamine along with essence and colors. The organoleptic properties and physicochemical parameters (like stickiness, texture, grittiness, viscosity, drug content and pH) of the formulations were determined. Techniques like FT-IR analysis, differential scanning calorimetry analysis, X-Ray diffraction, etc were studied exhaustively to determine the characteristics of the optimized formulation (F9). In-vitro dissolution study was carried out in simulated gastric fluid without enzyme. The hypoglycemic potential of the optimized formulation (F9) was studied on Swiss albino rat and the results were compared with standard drug metformin. This research opened new doors for nutraceutical research that have perspectives of commercialization as OTC products in near future.
Loading....